A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

NCT01285635 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

OTHER

Sponsor class

Stopped drug is no longer manufactured

Conditions

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

DRUG: AT-101
DRUG: Docetaxel

Sponsor

University of Michigan Rogel Cancer Center